Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 199.07

-3.4%

Nov 20 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mudcat who wrote (28440)	3/2/1999 9:10:00 AM
From: Henry Niman	Read Replies (2) of 32384

Targretin synergizes with SERMs, of which LGND's partners (PFE and AHP) have 4 compounds (Droloxifene, CP-366,156, TSE424, ERA-937) in the clinic. Breast cancer will be treated with combination treatments (which is the subject of LGND's LLY alliance in breast cancer - combining Rexinoids with SERMs). Several of LGND's current Phase II Targretin trials are in combination with Tamoxifen, the only approved SERM for treating breast cancer. Your analysis is way off base. Yesterday's announcement is positive for the long term. The current milestone payment will have little impact on bottom line near term.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next